NuCana (NCNA) Receivables - Other (2016 - 2024)
NuCana (NCNA) reported Receivables - Other of $23103.0 for Q4 2024, up 3.41% on a YoY basis from $22340.7 in Q1 2024, and up 3.41% sequentially from $22340.7 in Q4 2023.
NuCana (NCNA) Receivables - Other (2016 - 2024) Analysis & Trends
NuCana (NCNA) has 9 years of Receivables - Other data on file, last reported at $23103.0 in Q4 2024.
- For the quarter ending Q4 2024, Receivables - Other rose 3.41% year-over-year to $23103.0; the trailing twelve-month figure through Dec 2024 stood at $23103.0 (up 3.41% YoY), and the FY2024 full-year result was $23009.0, up 2.77% from the prior year.
- Receivables - Other advanced to $23103.0 in Q4 2024, from $22340.7 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $23103.0 in Q4 2024 to a low of $11884.1 in Q4 2020.
- A 5-year average of $17176.2 and a median of $16421.0 in 2022 frame the typical range for Receivables - Other.
- Across the five-year window, Receivables - Other slumped 76.89% in 2020 and surged 36.05% in 2023, its largest moves.
- Tracing NCNA's Receivables - Other over 5 years: stood at $11884.1 in 2020, then climbed by 2.09% to $12132.1 in 2021, then soared by 35.35% to $16421.0 in 2022, then soared by 36.05% to $22340.7 in 2023, then increased by 3.41% to $23103.0 in 2024.
- Business Quant data shows NCNA's Receivables - Other at $23103.0 in Q4 2024, $22340.7 in Q4 2023, and $16421.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 23,103.03 |
| Dec 31, 2024 | 23,103.03 |
| Dec 31, 2023 | 22,340.73 |
| Dec 31, 2023 | 22,340.73 |
| Dec 31, 2022 | 16,421.00 |
| Dec 31, 2022 | 16,421.00 |
| Dec 31, 2021 | 12,132.10 |
| Dec 31, 2021 | 12,132.10 |
| Dec 31, 2020 | 11,884.06 |
| Dec 31, 2020 | 11,884.06 |
| Dec 31, 2019 | 51,429.00 |
| Dec 31, 2019 | 51,429.00 |
| Dec 31, 2018 | 12,867.67 |
| Dec 31, 2018 | 12,867.67 |
| Dec 31, 2017 | 11,948.98 |
| Dec 31, 2017 | 11,948.98 |
| Dec 31, 2016 | 238,698.67 |
| Dec 31, 2016 | 238,698.67 |